Immune Checkpoint Inhibition—Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity

Uma Thanarajasingam, Noha Abdel-Wahab

Research output: Contribution to journalReview articlepeer-review

Abstract

Mechanisms of immune checkpoints and their role in autoimmunity are discussed in the context of immune checkpoint inhibitor (ICI) therapy for cancer. The updated clinical spectrum of immune-related adverse events (irAEs), with an in-depth discussion of rheumatic irAEs, is presented. The relationship between ICI-induced loss of self-tolerance in cancer and the implications for understanding of irAEs, rheumatic irAEs in particular, is overviewed.

Original languageEnglish (US)
Pages (from-to)587-603
Number of pages17
JournalRheumatic Disease Clinics of North America
Volume46
Issue number3
DOIs
StatePublished - Aug 2020

Keywords

  • Autoimmunity
  • Immune checkpoint inhibitors
  • Immune-related adverse events
  • Rheumatic diseases
  • Tolerance

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Immune Checkpoint Inhibition—Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity'. Together they form a unique fingerprint.

Cite this